Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|S1507||SWOG||A Phase II Trial of Trametinib with Docetaxel in Patients with Kras Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1512||SWOG||A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM)||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1513||SWOG||Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|S1600||SWOG||A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes||Cancer Prevention and Control CIRB||Available to Open|
|S1602||SWOG||A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Nave High-Grade Non-Muscle Invasive Bladder Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1605||SWOG||Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1607||SWOG||A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients with Advanced Melanoma who have Progressed on ANTI-PD1/L1 Based Therapy||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1608||SWOG||Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1609||SWOG||DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1612||SWOG||A Randomized Phase II/III Trial of "Novel Therapeutics" versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older||Adult CIRB - Late Phase Emphasis||Available to Open|